@article{10653,
  keywords = {*Cardiovascular Diseases/epidemiology/prevention & control, *Diabetes Mellitus, Type 2/complications/drug therapy/epidemiology, *Dipeptidyl-Peptidase IV Inhibitors/therapeutic use, England, Female, Germany, Glucose, Humans, Japan, Middle Aged, Norway, Republic of Korea, Sodium, *Sodium-Glucose Transporter 2 Inhibitors/therapeutic use, Sweden/epidemiology, DPP-IV inhibitor, SGLT2 inhibitor, dapagliflozin, diabetic nephropathy, heart failure, Observational study},
  author = {K. Birkeland and J. Bodegard and A. Banerjee and D. Kim and A. Norhammar and J. Eriksson and M. Thuresson and S. Okami and K. Ha and N. Kossack and J. Mamza and R. Zhang and T. Yajima and I. Komuro and T. Kadowaki},
  title = {Lower cardiorenal risk with sodium-glucose cotransporter-2 inhibitors versus dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes without cardiovascular and renal diseases: A large multinational observational study},
  year = {2021},
  journal = {Diabetes Obes Metab},
  volume = {23},
  edition = {2020/09/08},
  number = {1},
  pages = {75-85},
  isbn = {1462-8902 (Print)1462-8902},
  doi = {10.1111/dom.14189},
  note = {1463-1326
Birkeland, Kåre I
Orcid: 0000-0003-3002-6933
Bodegard, Johan
Orcid: 0000-0001-5423-3967
Banerjee, Amitava
Kim, Dae Jung
Orcid: 0000-0003-1025-2044
Norhammar, Anna
Eriksson, Jan W
Orcid: 0000-0002-2639-9481
Thuresson, Marcus
Okami, Suguru
Orcid: 0000-0003-4402-0209
Ha, Kyoung Hwa
Kossack, Nils
Mamza, Jil Billy
Zhang, Ruiqi
Yajima, Toshitaka
Komuro, Issei
Kadowaki, Takashi
Journal Article
Observational Study
Research Support, Non-U.S. Gov't
Diabetes Obes Metab. 2021 Jan;23(1):75-85. doi: 10.1111/dom.14189. Epub 2020 Sep 28.},
  language = {eng},
}